

In the Claims

Please amend the claims follows:

Sub I1
#1 37. (Four times amended) An SCR3 derivative polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the SCR3 derivative polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1.

Sub I2
#2 38. (Twice amended) The SCR3 derivative polypeptide according to claim 37, further comprising a cysteine residue at the carboxyl terminus and the amino terminus of the polypeptide, thereby providing a capability to form a cyclic polypeptide via formation of a disulfide bond.

Sub I3
#3 39. (Three times amended) The SCR3 derivative polypeptide according to claim 37, further comprising a chemically reactive amino acid residue located at least one position selected from the group consisting of the carboxyl terminus and the amino terminus of the polypeptide.

Sub I4 40. (Twice amended) The SCR3 derivative polypeptide according to claim 39, wherein the chemically reactive amino acid residue is derivatized or derivatizable.

#4 41. (Twice amended) The SCR3 derivative polypeptide according to claim 40, wherein the terminal amino acid residue is cysteine derivatized with S-(2-pyridyl) dithio.

42. (Twice amended) The SCR3 derivative polypeptide according to claim 37, wherein the polypeptide is altered to remove chemically reactive amino acid residues.

Sub I5 43. (Four times amended) A multimeric SCR3 derivative polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative polypeptide comprises at least two polypeptide constituents that comprise a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the polypeptide constituents have at least one amino acid sequence selected from the group consisting of:

#5 (a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, wherein the polypeptide constituents do not comprise a mature short consensus repeat-3 and the polypeptide constituents are linked to a core structure.

H6 Sub I6 44. (Twice amended) The multimeric SCR3 derivative polypeptide according to claim 43, wherein the core structure comprises a derivative of lysine.

Sub I7 45. (Amended) The multimeric SCR3 derivative polypeptide according to claim 43, wherein the core structure is (lys)₄(lys)₂ lys ala or Tris (aminoethyl) amine and 1,2,4,5 benzene tetracarboxylic acid.

H7 46. (Amended) The multimeric SCR3 derivative polypeptide according to claim 43, wherein the multimeric polypeptide comprises two to eight SCR3-derived polypeptides.

Sub I8
H8 47. (Amended) The multimeric SCR3 derivative polypeptide according to claim 43, which comprises (Lys)₄ (Lys)₂ Ala-OH) linked through N-(ε-thiopropionyl) linkers that are disulfide bonded to cysteine thiol of the polypeptide SGGRKVFELVGPSIYC.

Sub I9
H9 48. (Four times amended) A chimeric polypeptide comprising a host protein and as an insert an SCR3 derived polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the SCR3 derived polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

#9
Cont

(b) amino acids 11-20 of SEQ ID NO: 1,
wherein the SCR3 derived polypeptide is inserted into a non-essential region of
the host protein.

51. (Twice amended) The SCR3 derivative polypeptide according to claim
37, wherein the SCR3 derivative polypeptide is selected from the group consisting of:
linear CNPGSGGRKVFELVGEPSIYC (SEQ ID NO: 4);
cyclic CNPGSGGRKVFELVGEPSIYC (SEQ ID NO: 4);
SGGRKVFELVGEPSIYC (SEQ ID NO: 5);
CGGRKVFC (SEQ ID NO: 7); and
FELVGEPSIYSTSNDDQVGIWSG (SEQ ID NO: 8).

52. (Four times amended) A process for preparing an SCR3 derivative
polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative
polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the
SCR3 derivative polypeptide has at least one amino acid sequence selected from the
group consisting of:

- (a) amino acids 6-11 of SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1, comprising the step of:
condensing peptide units.

53. (Four times amended) A process for preparing an SCR3 derivative polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the SCR3 derivative polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, comprising the step of:
expressing DNA encoding the polypeptide in a recombinant host cell, and recovering the polypeptide.

54. (Four times amended) An isolated polynucleotide encoding an SCR3 derivative polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the SCR3 derivative polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1.

55. (Amended) The isolated polynucleotide according to claim 54, wherein the polynucleotide is in an expression vector.

56. (Amended) The isolated polynucleotide according to claim 54, wherein the polynucleotide is in an expression vector and the expression vector is in a host cell.

57. (Four times amended) A pharmaceutical composition comprising
(1) a therapeutically effective amount of an SCR3 derivative polypeptide having only a partial SCR3 sequence, wherein the SCR3 derivative polypeptide comprises a 6 to 23 amino acid portion of SEQ ID NO: 1, and wherein the SCR3 derivative polypeptide has at least one amino acid sequence selected from the group consisting of:

- (a) amino acids 6-11 of SEQ ID NO: 1, and
- (b) amino acids 11-20 of SEQ ID NO: 1, and
- (2) a pharmaceutically acceptable carrier or excipient.